Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
US12006354B2 · kind B2 · utility
0Cited by
11References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 22, 2018 |
| Grant date | Jun 11, 2024 |
| Priority date | — |
| Expiry date | Nov 30, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N5/0682
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and producibility over recombinant human IL2 formulations such as Proleukin®.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.